US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
TW321649B
(de)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
JPH11507329A
(ja)
*
|
1995-04-27 |
1999-06-29 |
ゼネカ リミテッド |
キナゾリン誘導体
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
AU719434B2
(en)
|
1996-02-13 |
2000-05-11 |
Astrazeneca Ab |
Quinazoline derivatives as VEGF inhibitors
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
CA2244897C
(en)
|
1996-03-05 |
2006-04-11 |
Zeneca Limited |
4-anilinoquinazoline derivatives
|
BR9708640B1
(pt)
|
1996-04-12 |
2013-06-11 |
|
inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo.
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
US5985877A
(en)
†
|
1997-08-15 |
1999-11-16 |
Cephalon, Inc. |
Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
|
US6294532B1
(en)
|
1997-08-22 |
2001-09-25 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US6864227B1
(en)
*
|
1998-04-13 |
2005-03-08 |
California Institute Of Technology |
Artery-and vein-specific proteins and uses therefor
|
US6887674B1
(en)
*
|
1998-04-13 |
2005-05-03 |
California Institute Of Technology |
Artery- and vein-specific proteins and uses therefor
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
IL140855A0
(en)
|
1998-08-18 |
2002-02-10 |
Univ California |
Preventing airway mucus production by administration of egf-r antagonists
|
US7354894B2
(en)
*
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
HUP0103386A3
(en)
|
1998-08-21 |
2002-07-29 |
Parker Hughes Inst St Paul |
Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
BR9914164A
(pt)
|
1998-09-29 |
2001-06-26 |
American Cyanamid Co |
Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto
|
EP1135153B1
(de)
*
|
1998-11-20 |
2005-04-27 |
Genentech, Inc. |
Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
|
ID29800A
(id)
|
1999-02-27 |
2001-10-11 |
Boehringer Ingelheim Pharma |
Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase
|
DE19911509A1
(de)
*
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
CA2373815A1
(en)
*
|
1999-05-14 |
2000-11-23 |
Imclone Systems Incorporated |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
EE04748B1
(et)
|
1999-06-21 |
2006-12-15 |
Boehringer Ingelheim Pharma Kg |
Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
GB9925958D0
(en)
*
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
SI1676845T1
(sl)
|
1999-11-05 |
2008-10-31 |
Astrazeneca Ab |
Novi kinazolinski derivati
|
US20020002169A1
(en)
|
1999-12-08 |
2002-01-03 |
Griffin John H. |
Protein kinase inhibitors
|
GB0002952D0
(en)
*
|
2000-02-09 |
2000-03-29 |
Pharma Mar Sa |
Process for producing kahalalide F compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0008368D0
(en)
*
|
2000-04-06 |
2000-05-24 |
Astrazeneca Ab |
Combination product
|
SI1274692T1
(sl)
|
2000-04-07 |
2006-12-31 |
Astrazeneca Ab |
Kinazolinske spojine
|
EP1170011A1
(de)
*
|
2000-07-06 |
2002-01-09 |
Boehringer Ingelheim International GmbH |
Neue Verwendung von Inhibitoren der Rezeptoren des epidermalen Wachstumsfaktors
|
JP2004527456A
(ja)
*
|
2000-08-09 |
2004-09-09 |
イムクローン システムズ インコーポレイティド |
Egf受容体拮抗剤による過増殖性の疾患の治療
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
DE10042059A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE10042058A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6939866B2
(en)
*
|
2000-10-13 |
2005-09-06 |
Astrazeneca Ab |
Quinazoline derivatives
|
ATE355275T1
(de)
|
2000-10-20 |
2006-03-15 |
Eisai R&D Man Co Ltd |
Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
|
DE10206505A1
(de)
*
|
2002-02-16 |
2003-08-28 |
Boehringer Ingelheim Pharma |
Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern
|
US7776315B2
(en)
|
2000-10-31 |
2010-08-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and additional active ingredients
|
ATE502928T1
(de)
|
2000-11-01 |
2011-04-15 |
Millennium Pharm Inc |
Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
RU2322981C2
(ru)
|
2001-02-19 |
2008-04-27 |
Новартис Аг |
Комбинация и способ предупреждения рака молочной железы
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
PT1392313E
(pt)
|
2001-05-16 |
2007-07-17 |
Novartis Ag |
Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
DE10204462A1
(de)
*
|
2002-02-05 |
2003-08-07 |
Boehringer Ingelheim Pharma |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
WO2003066602A1
(fr)
|
2002-02-06 |
2003-08-14 |
Ube Industries, Ltd. |
Procede relatif a l'elaboration d'un compose 4-aminoquinazoline
|
GB0204392D0
(en)
*
|
2002-02-26 |
2002-04-10 |
Astrazeneca Ab |
Pharmaceutical compound
|
PL208114B1
(pl)
*
|
2002-02-26 |
2011-03-31 |
Astrazeneca Ab |
Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie
|
US7612077B2
(en)
*
|
2002-02-26 |
2009-11-03 |
Astrazeneca Ab |
Crystalline forms of the anti-cancer compound ZD1839
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
TW200813014A
(en)
*
|
2002-03-28 |
2008-03-16 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
DE60311788T2
(de)
*
|
2002-04-16 |
2007-11-22 |
Astrazeneca Ab |
Kombinationstherapie zur behandlung von krebs
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
JP5227492B2
(ja)
|
2002-05-16 |
2013-07-03 |
ノバルティス アーゲー |
癌におけるedgレセプター結合剤の使用
|
US20040048887A1
(en)
*
|
2002-07-09 |
2004-03-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
|
CA2491191C
(en)
|
2002-07-15 |
2014-02-04 |
Exelixis, Inc. |
Receptor-type kinase modulators and methods of use
|
RU2338751C2
(ru)
|
2002-07-15 |
2008-11-20 |
Дженентек, Инк. |
СПОСОБЫ ИДЕНТИФИКАЦИИ ОПУХОЛЕЙ, ВОСПРИИМЧИВЫХ К ЛЕЧЕНИЮ АНТИТЕЛАМИ ПРОТИВ ErbB2
|
GB0221245D0
(en)
*
|
2002-09-13 |
2002-10-23 |
Astrazeneca Ab |
Chemical process
|
ES2562177T3
(es)
|
2002-09-27 |
2016-03-02 |
Xencor Inc. |
Variantes de Fc optimizadas y métodos para su generación
|
GB0223854D0
(en)
*
|
2002-10-12 |
2002-11-20 |
Astrazeneca Ab |
Therapeutic treatment
|
GB0304367D0
(en)
*
|
2003-02-26 |
2003-04-02 |
Pharma Mar Sau |
Methods for treating psoriasis
|
AU2003291394B2
(en)
|
2002-11-20 |
2009-06-25 |
Array Biopharma, Inc |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
WO2004060400A1
(ja)
*
|
2003-01-06 |
2004-07-22 |
Mitsubishi Pharma Corp |
上皮成長因子受容体を分子標的とする抗精神病薬
|
RS20050532A
(en)
|
2003-01-14 |
2007-12-31 |
Arena Pharmaceuticals Inc., |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
GB0302882D0
(en)
*
|
2003-02-07 |
2003-03-12 |
Univ Cardiff |
Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
EP1604665B1
(de)
|
2003-03-10 |
2011-05-11 |
Eisai R&D Management Co., Ltd. |
C-kit kinase-hemmer
|
US7381410B2
(en)
*
|
2003-03-12 |
2008-06-03 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
AU2004220525B2
(en)
*
|
2003-03-12 |
2011-03-31 |
Vasgene Therapeutics, Inc. |
Nucleic acid compounds for inhibiting angiogenesis and tumor growth
|
EP1622941A2
(de)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Methode zur produktion von anti-egfr antikörpern
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0310401D0
(en)
*
|
2003-05-07 |
2003-06-11 |
Astrazeneca Ab |
Therapeutic agent
|
JP4944613B2
(ja)
|
2003-05-19 |
2012-06-06 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
免疫抑制化合物および組成物
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
JO2785B1
(en)
*
|
2003-05-27 |
2014-03-15 |
شركة جانسين فارماسوتيكا ان. في |
Quinazoline derivatives
|
KR101126560B1
(ko)
|
2003-05-30 |
2012-04-05 |
도꾜 다이가꾸 |
약제 반응 예측 방법
|
DE10326186A1
(de)
*
|
2003-06-06 |
2004-12-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
WO2005001053A2
(en)
|
2003-06-09 |
2005-01-06 |
Samuel Waksal |
Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
TW201319088A
(zh)
|
2003-07-18 |
2013-05-16 |
Amgen Inc |
對肝細胞生長因子具專一性之結合劑
|
GB0317663D0
(en)
*
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Pharmaceutical composition
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
UY28441A1
(es)
*
|
2003-07-29 |
2005-02-28 |
Astrazeneca Ab |
Derivados de quinazolina
|
GB0320793D0
(en)
*
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Chemical process
|
GB0321066D0
(en)
*
|
2003-09-09 |
2003-10-08 |
Pharma Mar Sau |
New antitumoral compounds
|
SI1667991T1
(sl)
*
|
2003-09-16 |
2008-10-31 |
Astrazeneca Ab |
Kinazolinski derivati kot inhibitorji tirozin kinaze
|
CA2541100A1
(en)
*
|
2003-09-16 |
2005-03-24 |
Astrazenca Ab |
Quinazoline derivatives
|
JP2007505878A
(ja)
*
|
2003-09-19 |
2007-03-15 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
WO2005028469A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
US20070043010A1
(en)
*
|
2003-09-25 |
2007-02-22 |
Astrazeneca Uk Limited |
Quinazoline derivatives
|
ATE517091T1
(de)
|
2003-09-26 |
2011-08-15 |
Exelixis Inc |
C-met-modulatoren und verwendungsverfahren
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
SG149815A1
(en)
|
2003-11-06 |
2009-02-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
WO2005044788A1
(ja)
|
2003-11-11 |
2005-05-19 |
Eisai Co., Ltd. |
ウレア誘導体およびその製造方法
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2004298448B2
(en)
|
2003-12-18 |
2010-09-09 |
Janssen Pharmaceutica N.V. |
Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
|
WO2005062041A1
(en)
*
|
2003-12-24 |
2005-07-07 |
Astrazeneca Ab |
Pharmaceutical dissolution testing using a non-ionic surfactant
|
WO2005070909A1
(en)
*
|
2004-01-22 |
2005-08-04 |
Natco Pharma Limited |
An improved process for the preparation of gefitinib
|
CN1914182B
(zh)
|
2004-02-03 |
2011-09-07 |
阿斯利康(瑞典)有限公司 |
喹唑啉衍生物
|
CN102718867A
(zh)
|
2004-03-12 |
2012-10-10 |
瓦斯基因治疗公司 |
结合ephb4、抑制血管发生和肿瘤生长的抗体
|
WO2005090406A2
(en)
*
|
2004-03-12 |
2005-09-29 |
Vasgene Therapeutics, Inc. |
Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
|
MXPA06010715A
(es)
*
|
2004-03-19 |
2007-05-23 |
Imclone Systems Inc |
Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
|
EP3611273A1
(de)
|
2004-03-31 |
2020-02-19 |
The General Hospital Corporation |
Verfahren zur bestimmung des ansprechens von krebs auf den epidermalen wachstumsfaktorrezeptor gerichtete behandlungen
|
WO2005097134A2
(en)
*
|
2004-03-31 |
2005-10-20 |
The Scripps Research Institute |
Quinazoline based protein kinase inhibitors
|
PL2253614T3
(pl)
|
2004-04-07 |
2013-03-29 |
Novartis Ag |
Inhibitory IAP
|
WO2005107747A2
(en)
*
|
2004-05-06 |
2005-11-17 |
Bioresponse, Llc |
Diindolymethane formulations for the treatment of leiomyomas
|
JP4205757B2
(ja)
*
|
2004-05-06 |
2009-01-07 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
4−フェニルアミノ−キナゾリン−6−イル−アミド
|
MXPA06014065A
(es)
|
2004-06-01 |
2007-01-31 |
Genentech Inc |
Conjugados de droga-anticuerpo y metodos.
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
WO2006002422A2
(en)
|
2004-06-24 |
2006-01-05 |
Novartis Vaccines And Diagnostics Inc. |
Compounds for immunopotentiation
|
EP2471813B1
(de)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimierte Fc-Varianten
|
AU2005283422C1
(en)
|
2004-09-17 |
2017-02-02 |
Eisai R & D Management Co., Ltd. |
Medicinal composition
|
CN101065151B
(zh)
|
2004-09-23 |
2014-12-10 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
US20060204512A1
(en)
*
|
2004-09-23 |
2006-09-14 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
MX2007006230A
(es)
|
2004-11-30 |
2007-07-25 |
Amgen Inc |
Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
JO3088B1
(ar)
*
|
2004-12-08 |
2017-03-15 |
Janssen Pharmaceutica Nv |
مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
|
CN101124228B
(zh)
|
2004-12-14 |
2011-06-15 |
阿斯利康(瑞典)有限公司 |
用作抗肿瘤药物的吡唑并嘧啶化合物
|
CA2593084C
(en)
|
2004-12-30 |
2014-03-18 |
Bioresponse, Llc |
Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
US20080161251A1
(en)
|
2005-01-21 |
2008-07-03 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
CN101141981A
(zh)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
GB0501999D0
(en)
*
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
CN113952338A
(zh)
|
2005-02-03 |
2022-01-21 |
综合医院公司 |
治疗吉非替尼耐药性癌症的方法
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
DK1850874T3
(da)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab
|
WO2006090413A1
(en)
*
|
2005-02-23 |
2006-08-31 |
Natco Pharma Limited |
Novel crystalline form of gefitinib and a process for its preparation
|
AU2006217738A1
(en)
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
EP1859793B1
(de)
*
|
2005-02-28 |
2011-04-20 |
Eisai R&D Management Co., Ltd. |
Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
|
US20060216288A1
(en)
*
|
2005-03-22 |
2006-09-28 |
Amgen Inc |
Combinations for the treatment of cancer
|
MX2007012778A
(es)
*
|
2005-04-12 |
2008-01-11 |
Elan Pharma Int Ltd |
Formulaciones de derivados de quinazolina nanoparticuladas.
|
ES2601503T3
(es)
|
2005-04-19 |
2017-02-15 |
Novartis Ag |
Composición farmacéutica
|
WO2006119676A1
(fr)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d'une maladie tumorale
|
WO2006119674A1
(fr)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
|
WO2006119673A1
(fr)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
|
EP1885187B1
(de)
|
2005-05-13 |
2013-09-25 |
Novartis AG |
Verfahren zur behandlung von arzneimittelresistentem krebs
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
PT2100618E
(pt)
|
2005-06-17 |
2014-04-07 |
Philadelphia Health & Educatio |
Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático
|
US7405227B2
(en)
*
|
2005-07-18 |
2008-07-29 |
Bipar Sciences, Inc. |
Treatment of cancer
|
EP1925941B1
(de)
*
|
2005-08-01 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Verfahren zur vorhersage der wirksamkeit eines vaskularisierungsinhibitors
|
EP1925676A4
(de)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
Testverfahren für die wirkung eines vaskularisierungsinhibitors
|
EP1917528B1
(de)
|
2005-08-24 |
2011-08-17 |
Bristol-Myers Squibb Company |
Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
|
CN1300118C
(zh)
*
|
2005-08-25 |
2007-02-14 |
江苏吴中苏药医药开发有限责任公司 |
4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-(3-吗啉丙氧基)喹唑啉的制备方法
|
WO2007026864A1
(ja)
*
|
2005-09-01 |
2007-03-08 |
Eisai R & D Management Co., Ltd. |
崩壊性の改善された医薬組成物の製造方法
|
EP1928861B1
(de)
|
2005-09-20 |
2010-11-17 |
AstraZeneca AB |
4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
|
AU2006294873A1
(en)
*
|
2005-09-23 |
2007-04-05 |
Vasgene Therapeutics, Inc. |
Use of EphrinB2 directed agents for the treatment or prevention of viral infections
|
CA2626326C
(en)
|
2005-11-04 |
2021-02-16 |
Wyeth |
Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
|
CA2627598C
(en)
|
2005-11-07 |
2013-06-25 |
Eisai R & D Management Co., Ltd. |
Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
|
EP1948179A1
(de)
|
2005-11-11 |
2008-07-30 |
Boehringer Ingelheim International GmbH |
Chinazolin-derivate zur behandlung von krebserkrankungen
|
AU2006314444C1
(en)
|
2005-11-21 |
2018-01-04 |
Novartis Ag |
Neuroendocrine tumor treatment using mTOR inhibitors
|
EP1964837A4
(de)
*
|
2005-11-22 |
2010-12-22 |
Eisai R&D Man Co Ltd |
Antitumormittel gegen multiples myelom
|
US7977346B2
(en)
*
|
2006-01-17 |
2011-07-12 |
Guoqing Paul Chen |
Spiro compounds and methods of use
|
CN101003514A
(zh)
|
2006-01-20 |
2007-07-25 |
上海艾力斯医药科技有限公司 |
喹唑啉衍生物、其制备方法及用途
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
AR059066A1
(es)
*
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
CN101415409B
(zh)
|
2006-04-05 |
2012-12-05 |
诺瓦提斯公司 |
用于治疗癌症的治疗剂的组合
|
AU2007234382B2
(en)
|
2006-04-05 |
2011-06-09 |
Novartis Ag |
Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
|
AR060358A1
(es)
*
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
US20070293491A1
(en)
|
2006-04-19 |
2007-12-20 |
Novartis Vaccines And Diagnostics, Inc. |
Indazole compounds and methods for inhibition of cdc7
|
PE20080695A1
(es)
|
2006-04-27 |
2008-06-28 |
Banyu Pharma Co Ltd |
Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
|
WO2007128820A1
(en)
|
2006-05-09 |
2007-11-15 |
Novartis Ag |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
CN101443009A
(zh)
*
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
US20100279327A1
(en)
*
|
2006-06-12 |
2010-11-04 |
Bipar Sciences, Inc. |
Method of treating diseases with parp inhibitors
|
US20070292883A1
(en)
*
|
2006-06-12 |
2007-12-20 |
Ossovskaya Valeria S |
Method of treating diseases with PARP inhibitors
|
JPWO2008001956A1
(ja)
*
|
2006-06-29 |
2009-12-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
肝線維症治療剤
|
ES2569428T3
(es)
*
|
2006-07-13 |
2016-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina como MTKI
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
ME01786B
(me)
|
2006-08-14 |
2014-09-20 |
Xencor Inc |
Optimizovana antitela usmerena na cd19
|
EP2065372B1
(de)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Antitumormittel gegen undifferenzierten magenkrebs
|
JP2008081492A
(ja)
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
|
EP2061479A4
(de)
*
|
2006-09-05 |
2010-08-04 |
Bipar Sciences Inc |
Fettsäuresynthesehemmung durch parp-hemmer und behandlungsverfahren damit
|
EP2059498A4
(de)
*
|
2006-09-05 |
2011-01-12 |
Bipar Sciences Inc |
Krebsbehandlung
|
CA2662587C
(en)
*
|
2006-09-11 |
2013-08-06 |
Curis, Inc. |
Quinazoline based egfr inhibitors
|
ES2372217T3
(es)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
|
SI2068880T1
(sl)
|
2006-09-18 |
2012-08-31 |
Boehringer Ingelheim Int |
Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
|
BRPI0717564A2
(pt)
|
2006-09-29 |
2013-10-22 |
Novartis Ag |
Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008046242A1
(fr)
*
|
2006-10-16 |
2008-04-24 |
Institute Of Mataria Medica, Chinese Academy Of Medical Sciences |
Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
|
US8586621B2
(en)
|
2006-10-27 |
2013-11-19 |
Michael A. Zeligs |
Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
|
KR20090091119A
(ko)
*
|
2006-10-27 |
2009-08-26 |
얀센 파마슈티카 엔.브이. |
뇌암을 치료하거나 예방하기 위한 mt 키나아제 저해제의 용도
|
US7851623B2
(en)
*
|
2006-11-02 |
2010-12-14 |
Astrazeneca Ab |
Chemical process
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
RU2009126633A
(ru)
*
|
2006-12-13 |
2011-01-20 |
Джилид Сайэнс, Инк. (US) |
Монофосфатные соединения, способ их получения, аэрозольный препарат (варианты) и способ профилактики и/или лечения бронхостеноза посредством указанных соединений
|
US7687522B2
(en)
|
2006-12-20 |
2010-03-30 |
Amgen Inc. |
Substituted pyridines and pyrimidines and their use in treatment of cancer
|
US7977336B2
(en)
|
2006-12-28 |
2011-07-12 |
Banyu Pharmaceutical Co. Ltd |
Aminopyrimidine derivatives as PLK1 inhibitors
|
EP2118069B1
(de)
|
2007-01-09 |
2014-01-01 |
Amgen Inc. |
Bis-aryl amid-derivate zur krebsbehandlung
|
WO2008093855A1
(ja)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
未分化型胃癌治療用組成物
|
AU2008212999A1
(en)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
AU2008216327A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combination of LBH589 with other therapeutic agents for treating cancer
|
CA2676173A1
(en)
|
2007-02-16 |
2008-08-28 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
|
EP2132573B1
(de)
|
2007-03-02 |
2014-04-23 |
Genentech, Inc. |
Voraussage der reaktion auf einen her-dimerisationshemmer auf basis niedriger her3-expression
|
WO2008121346A1
(en)
*
|
2007-03-30 |
2008-10-09 |
Massachusetts Institute Of Technology |
Methods for identifying compounds that modulate neurotrophic factor signaling
|
KR20100017101A
(ko)
|
2007-04-16 |
2010-02-16 |
시플라 리미티드 |
게피티닙의 제조방법
|
EP2176298B1
(de)
|
2007-05-30 |
2017-11-15 |
Xencor, Inc. |
Verfahren und zusammensetzungen zur hemmung von cd32b-expressionszellen
|
PL2171090T3
(pl)
|
2007-06-08 |
2013-09-30 |
Genentech Inc |
Markery ekspresji genów odporności guza na leczenie hamujące HER2
|
AU2008265104B2
(en)
*
|
2007-06-21 |
2013-09-12 |
Janssen Pharmaceutica Nv |
Indolin-2-ones and aza-indolin-2-ones
|
EP2185562B1
(de)
|
2007-07-27 |
2015-12-02 |
Janssen Pharmaceutica, N.V. |
Zur behandlung proliferativer erkrankungen geeignete pyrrolopyrimidine
|
JP5749009B2
(ja)
*
|
2007-08-13 |
2015-07-15 |
バスジーン セラピューティクス,インコーポレイテッドVasgenetherapeutics,Inc. |
EphB4に結合するヒト化抗体を利用する癌治療剤
|
SG10201500328QA
(en)
|
2007-08-21 |
2015-03-30 |
Amgen Inc |
Human c-fms antigen binding proteins
|
AU2008299896B2
(en)
|
2007-09-10 |
2012-02-02 |
Curis, Inc. |
Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
AU2008312400A1
(en)
*
|
2007-10-19 |
2009-04-23 |
Albert Einstein College Of Medicine Of Yeshiva University |
Improved antitumoral treatments
|
EP2211854A4
(de)
*
|
2007-10-19 |
2011-01-12 |
Bipar Sciences Inc |
Verfahren und zusammensetzungen zur behandlung von krebs mit parp-inhibitoren vom benzopyrontyp
|
CA2703489A1
(en)
|
2007-10-23 |
2009-04-30 |
Banyu Pharmaceutical Co., Ltd. |
Pyridone-substituted-dihydropyrazolopyrimidinone derivative
|
WO2009057139A2
(en)
|
2007-10-29 |
2009-05-07 |
Natco Pharma Limited |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
CA2704000C
(en)
|
2007-11-09 |
2016-12-13 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
EP2217244A4
(de)
*
|
2007-11-12 |
2011-08-31 |
Bipar Sciences Inc |
Behandlung von gebärmutterkrebs und eierstockkrebs mit einem parp-inhibitor allein oder in kombination mit antitumoralen mitteln
|
EP2217227B1
(de)
*
|
2007-11-12 |
2013-08-21 |
BiPar Sciences, Inc. |
Behandlung von brustkrebs mit 4-iodo-3-nitrobenzamid in kombination mit antitumoralen mitteln
|
WO2009067543A2
(en)
*
|
2007-11-19 |
2009-05-28 |
The Regents Of The University Of Colorado |
Treatment of histone deacetylase mediated disorders
|
AR069393A1
(es)
|
2007-11-21 |
2010-01-20 |
Imclone Systems Inc |
Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
|
EP2224804A4
(de)
*
|
2007-12-07 |
2011-06-01 |
Bipar Sciences Inc |
Behandlung von krebs mit kombinationen von topoisomerasehemmern und parp-hemmern
|
CN101952282A
(zh)
|
2007-12-20 |
2011-01-19 |
诺瓦提斯公司 |
用作pi 3激酶抑制剂的噻唑衍生物
|
SG187490A1
(en)
*
|
2008-01-18 |
2013-02-28 |
Natco Pharma Ltd |
6,7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
|
WO2009094216A1
(en)
*
|
2008-01-22 |
2009-07-30 |
Concert Pharmaceuticals Inc. |
Derivatives of gefitinib
|
CA2713930A1
(en)
*
|
2008-01-29 |
2009-08-06 |
Eisai R & D Management Co., Ltd. |
Combined use of angiogenesis inhibitor and taxane
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
WO2009095480A1
(en)
*
|
2008-01-30 |
2009-08-06 |
Pharma Mar, S.A. |
Improved antitumoral treatments
|
EP2245026B1
(de)
|
2008-02-07 |
2012-08-01 |
Boehringer Ingelheim International GmbH |
Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
RU2496500C2
(ru)
*
|
2008-03-05 |
2013-10-27 |
Новартис Аг |
Применение производных пиримидина для лечения egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, направленным против членов семейства egfr
|
US20110015135A1
(en)
*
|
2008-03-07 |
2011-01-20 |
Pharma Mar S.A. |
Antitumoral Treatments
|
EA020114B1
(ru)
|
2008-03-24 |
2014-08-29 |
Новартис Аг |
Производные арилсульфонамида в качестве ингибиторов матриксной металлопротеазы
|
CN101544609A
(zh)
|
2008-03-25 |
2009-09-30 |
上海艾力斯医药科技有限公司 |
4-苯胺喹唑啉衍生物的结晶形式
|
PT2260020E
(pt)
|
2008-03-26 |
2014-10-28 |
Novartis Ag |
Inibidores das desacetilases b baseados no hidroxamato
|
NZ589883A
(en)
|
2008-05-13 |
2012-06-29 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
|
NZ610482A
(en)
|
2008-05-14 |
2014-08-29 |
Genomic Health Inc |
Predictors of patient response to treatment with egf receptor inhibitors
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
ES2835349T3
(es)
|
2008-06-17 |
2021-06-22 |
Wyeth Llc |
Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
|
DE102008031040A1
(de)
|
2008-06-30 |
2009-12-31 |
Alexander Priv.-Doz. Dr. Dömling |
Iressa zur Anwendung in der Organtransplantation
|
CN105963313A
(zh)
|
2008-08-04 |
2016-09-28 |
惠氏有限责任公司 |
4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
|
US8648191B2
(en)
|
2008-08-08 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
CN101367793B
(zh)
*
|
2008-09-26 |
2013-09-11 |
中国科学院广州生物医药与健康研究院 |
一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
|
WO2010043050A1
(en)
|
2008-10-16 |
2010-04-22 |
Celator Pharmaceuticals Corporation |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
EP2349235A1
(de)
|
2008-11-07 |
2011-08-03 |
Triact Therapeutics, Inc. |
Verwendung von catecholbutan-derivaten in der krebstherapie
|
EP2370082A4
(de)
*
|
2008-12-01 |
2012-05-30 |
Univ Central Florida Res Found |
Für bauchspeichelkrebszellen zytotoxische arzneimittelzusammensetzung
|
WO2010071794A1
(en)
|
2008-12-18 |
2010-06-24 |
Novartis Ag |
New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
|
CA2747558A1
(en)
|
2008-12-18 |
2010-07-15 |
Novartis Ag |
New salts
|
IL294514A
(en)
|
2008-12-18 |
2022-09-01 |
Novartis Ag |
1-[4-[1[(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid mipomarate salt
|
TW202241853A
(zh)
|
2009-01-16 |
2022-11-01 |
美商艾克塞里克斯公司 |
包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
ES2396023T3
(es)
|
2009-01-29 |
2013-02-18 |
Novartis Ag |
Bencimidazoles sustituidos para el tratamiento de astrocitomas
|
AU2010218781A1
(en)
|
2009-02-25 |
2011-07-28 |
Msd K.K. |
Pyrimidopyrimidoindazole derivative
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
|
EP2401614A1
(de)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2403339B1
(de)
|
2009-03-06 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Tumorkombinationstherapie mit einem akt-hemmer und anderen antumormitteln
|
EP2408479A1
(de)
|
2009-03-18 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Kombinationskrebstherapie mit verabreichung eines egfr-hemmers und eines igf-1r-hemmers
|
TWI461211B
(zh)
|
2009-03-20 |
2014-11-21 |
Genentech Inc |
抗-her抗體
|
IL264349B2
(en)
|
2009-04-06 |
2024-01-01 |
Wyeth Llc |
Regimens containing neratinib for the treatment of cancer
|
US8530492B2
(en)
|
2009-04-17 |
2013-09-10 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
AU2010264698C1
(en)
|
2009-06-26 |
2013-05-16 |
Novartis Ag |
1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
HUE044629T2
(hu)
|
2009-07-06 |
2019-11-28 |
Boehringer Ingelheim Int |
Eljárás BIBW2992, annak sói, valamint e hatóanyagot tartalmazó szilárd gyógyászati készítmények szárítására
|
US9050341B2
(en)
*
|
2009-07-14 |
2015-06-09 |
Natco Pharma Limited |
Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
JP5781510B2
(ja)
|
2009-08-12 |
2015-09-24 |
ノバルティス アーゲー |
ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
|
PT2467141T
(pt)
|
2009-08-17 |
2019-02-06 |
Intellikine Llc |
Compostos heterocíclicos e suas utilizações
|
EP2467383A1
(de)
|
2009-08-20 |
2012-06-27 |
Novartis AG |
Heterocyclische oximverbindungen
|
BR112012008075A2
(pt)
|
2009-08-26 |
2016-03-01 |
Novartis Ag |
compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
|
KR20120093867A
(ko)
|
2009-09-10 |
2012-08-23 |
아이알엠 엘엘씨 |
비시클릭 헤테로아릴의 에테르 유도체
|
US20120220594A1
(en)
|
2009-10-30 |
2012-08-30 |
Bristol-Meyers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
WO2011054828A1
(en)
|
2009-11-04 |
2011-05-12 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful as mek inhibitors
|
TW201121570A
(en)
|
2009-11-12 |
2011-07-01 |
Genentech Inc |
A method of promoting dendritic spine density
|
EP2510110A1
(de)
|
2009-11-13 |
2012-10-17 |
Pangaea Biotech S.L. |
Molekulare biomarker zur vorhersage der reaktion auf tyrosinkinaseinhibitoren bei lungenkrebs
|
AU2010321533A1
(en)
|
2009-11-23 |
2012-05-31 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
KR20120123299A
(ko)
|
2009-12-04 |
2012-11-08 |
제넨테크, 인크. |
다중특이적 항체, 항체 유사체, 조성물 및 방법
|
JP5456908B2
(ja)
|
2009-12-08 |
2014-04-02 |
ノバルティス アーゲー |
ヘテロ環式スルホンアミド誘導体
|
AU2012265844A1
(en)
|
2009-12-08 |
2013-05-02 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
WO2011086053A1
(en)
|
2010-01-12 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
CN102146060B
(zh)
*
|
2010-02-09 |
2013-07-03 |
陕西师范大学 |
制备吉非替尼及其中间体的方法
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
CA2800230A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
WO2011113802A2
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
CA2794708C
(en)
|
2010-03-29 |
2021-11-16 |
Zymeworks Inc. |
Antibodies with enhanced or suppressed effector function
|
TWI406853B
(zh)
*
|
2010-04-07 |
2013-09-01 |
Dev Center Biotechnology |
Egfr與vegfr-2雙重抑制劑及其用途與製法
|
EP2558864A1
(de)
|
2010-04-16 |
2013-02-20 |
Genentech, Inc. |
Fox03a als prädiktiver biomarker zur hemmung des pi3k/akt-kinasesignalweges
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
EP2582681A1
(de)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Piperidinylsubstituierte 1,3-dihydro-benzoimidazol-2-ylidenaminderivate
|
WO2011157787A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
WO2011161217A2
(en)
|
2010-06-23 |
2011-12-29 |
Palacký University in Olomouc |
Targeting of vegfr2
|
ES2573515T3
(es)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
DK2612151T3
(en)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
BIOMARKETS AND METHODS OF TREATMENT
|
AR082974A1
(es)
|
2010-09-15 |
2013-01-23 |
Hoffmann La Roche |
Derivados de azabenzotiazol, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para tratar enfermedades inflamatorias
|
WO2012035078A1
(en)
|
2010-09-16 |
2012-03-22 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
SG188548A1
(en)
|
2010-09-22 |
2013-04-30 |
Arena Pharm Inc |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US9309322B2
(en)
|
2010-11-12 |
2016-04-12 |
Scott & White Healthcare (Swh) |
Antibodies to tumor endothelial marker 8
|
BR112013011520A2
(pt)
|
2010-11-19 |
2019-09-24 |
Hoffmann La Roche |
pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
|
US20130236467A1
(en)
|
2010-11-24 |
2013-09-12 |
Jeremy Griggs |
Multispecific antigen binding proteins targeting hgf
|
AU2011346567A1
(en)
|
2010-12-21 |
2013-07-25 |
Novartis Ag |
Bi-heteroaryl compounds as Vps34 inhibitors
|
EP2468883A1
(de)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
TW201309700A
(zh)
|
2011-01-31 |
2013-03-01 |
Novartis Ag |
新穎雜環衍生物
|
US20130324526A1
(en)
|
2011-02-10 |
2013-12-05 |
Novartis Ag |
[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
EP2492688A1
(de)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
CA2828713C
(en)
|
2011-03-04 |
2022-08-16 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compounds and methods of use
|
JP2014507465A
(ja)
|
2011-03-08 |
2014-03-27 |
ノバルティス アーゲー |
フルオロフェニル二環式ヘテロアリール化合物
|
AU2012225246B2
(en)
|
2011-03-10 |
2016-01-21 |
Omeros Corporation |
Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
US9295676B2
(en)
|
2011-03-17 |
2016-03-29 |
The Trustees Of The University Of Pennsylvania |
Mutation mimicking compounds that bind to the kinase domain of EGFR
|
CN103648500B
(zh)
|
2011-03-17 |
2016-05-04 |
宾夕法尼亚大学理事会 |
双功能酶制钳型分子的方法和用途
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
ES2543569T3
(es)
|
2011-03-23 |
2015-08-20 |
Amgen Inc. |
Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
|
RU2580609C2
(ru)
|
2011-04-18 |
2016-04-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое терапевтическое средство
|
EP2702173A1
(de)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Verwendung von emt-gensignaturen bei der entdeckung von krebswirkstoffen, -diagnostika und -behandlungen
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
EA023064B1
(ru)
|
2011-04-28 |
2016-04-29 |
Новартис Аг |
ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
|
CN102918029B
(zh)
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
ES2841809T3
(es)
|
2011-06-03 |
2021-07-09 |
Eisai R&D Man Co Ltd |
Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
|
US8859586B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
EA201490164A1
(ru)
|
2011-06-27 |
2014-04-30 |
Новартис Аг |
Твердые формы и соли производных тетрагидропиридопиримидина
|
CN107090038A
(zh)
|
2011-06-30 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
抗c‑met抗体配制剂
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
EP2742040B1
(de)
|
2011-08-12 |
2016-04-06 |
F.Hoffmann-La Roche Ag |
Indazol-verbindungen, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
|
WO2013025446A2
(en)
|
2011-08-12 |
2013-02-21 |
Omeros Corporation |
Anti-fzd10 monoclonal antibodies and methods for their use
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
EP2744824A1
(de)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Neuregulin-antikörper und verwendungen davon
|
KR20140057356A
(ko)
|
2011-08-31 |
2014-05-12 |
제넨테크, 인크. |
진단 마커
|
ES2691650T3
(es)
|
2011-09-15 |
2018-11-28 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
|
BR112014006643A2
(pt)
|
2011-09-20 |
2017-04-04 |
Hoffmann La Roche |
compostos de imidazopiridina, composições e métodos de uso dos mesmos
|
CN103012290B
(zh)
*
|
2011-09-28 |
2015-05-13 |
齐鲁制药有限公司 |
一种高纯度吉非替尼的制备方法
|
WO2013055530A1
(en)
|
2011-09-30 |
2013-04-18 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
|
EP2766497A1
(de)
|
2011-10-13 |
2014-08-20 |
Bristol-Myers Squibb Company |
Verfahren zur auswahl und behandlung von krebs bei patienten mit igf-1r/ir-hemmern
|
MX340452B
(es)
|
2011-10-28 |
2016-07-08 |
Novartis Ag |
Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
|
CN103102342B
(zh)
*
|
2011-11-14 |
2014-10-29 |
广东东阳光药业有限公司 |
氨基喹唑啉类衍生物及其盐和使用方法
|
CN103102345B
(zh)
*
|
2011-11-14 |
2015-06-03 |
广东东阳光药业有限公司 |
氨基喹唑啉类衍生物及其盐和使用方法
|
TWI577671B
(zh)
|
2011-11-14 |
2017-04-11 |
Sunshine Lake Pharma Co Ltd |
Aminoquinazoline derivatives and salts thereof and methods of use thereof
|
US8969341B2
(en)
|
2011-11-29 |
2015-03-03 |
Novartis Ag |
Pyrazolopyrrolidine compounds
|
CA2857114A1
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
CN103130729B
(zh)
*
|
2011-12-05 |
2015-07-15 |
齐鲁制药有限公司 |
一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法
|
CN103172576B
(zh)
*
|
2011-12-21 |
2015-08-05 |
沈阳药科大学 |
吉非替尼的苹果酸加成盐及其制备和应用
|
CA2859764C
(en)
|
2011-12-22 |
2019-12-31 |
Novartis Ag |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
CA2859862A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
CN104136429A
(zh)
|
2011-12-23 |
2014-11-05 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
CA2859869A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
KR20140107574A
(ko)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
EP2794589A1
(de)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
AU2013214254B2
(en)
|
2012-01-31 |
2016-04-21 |
Novartis Ag |
Method of treating cancer
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
SG11201405553YA
(en)
|
2012-03-08 |
2014-11-27 |
Halozyme Inc |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
EP2752413B1
(de)
|
2012-03-26 |
2016-03-23 |
Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences |
Chinazolinderivat und anwendung davon
|
EP2831115A1
(de)
|
2012-03-27 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Diagnose und behandlungen im zusammenhang mit her3-hemmern
|
MX371119B
(es)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
AU2013263043B2
(en)
|
2012-05-16 |
2016-06-16 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
KR101457453B1
(ko)
*
|
2012-05-31 |
2014-11-04 |
주식회사 종근당 |
게피티닙의 제조방법 및 이의 제조에 사용되는 중간체
|
US9789193B2
(en)
|
2012-06-15 |
2017-10-17 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
WO2014016848A2
(en)
|
2012-07-24 |
2014-01-30 |
Laurus Labs Private Limited |
Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
|
EP2879675B1
(de)
|
2012-08-06 |
2019-11-13 |
Duke University |
Auf hsp90 gerichtete verbindungen und verfahren
|
WO2014036022A1
(en)
|
2012-08-29 |
2014-03-06 |
Amgen Inc. |
Quinazolinone compounds and derivatives thereof
|
CN105377288B
(zh)
|
2012-11-05 |
2019-11-15 |
达纳-法伯癌症研究所股份有限公司 |
Xbp1、cd138和cs1肽的组合物制备药物的用途
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
CN103073509A
(zh)
*
|
2012-12-31 |
2013-05-01 |
广东先强药业有限公司 |
一类喹唑啉衍生物的制备方法
|
CN103910690A
(zh)
*
|
2013-01-06 |
2014-07-09 |
上海科胜药物研发有限公司 |
一种吉非替尼新晶型及其制备方法
|
WO2014108858A1
(en)
|
2013-01-10 |
2014-07-17 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Fatty acid synthase inhibitors
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
EP2948451B1
(de)
|
2013-01-22 |
2017-07-12 |
Novartis AG |
Substituierte purinonverbindungen
|
JP6463276B2
(ja)
|
2013-02-01 |
2019-01-30 |
ウェルスタット セラピューティクス コーポレイション |
抗炎症、抗真菌、抗寄生生物及び抗癌活性を有するアミン化合物
|
ES2760023T3
(es)
|
2013-02-20 |
2020-05-12 |
Univ Pennsylvania |
Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
JP2016509045A
(ja)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療し、薬剤耐性を防止する方法
|
AU2014223548A1
(en)
|
2013-02-26 |
2015-10-15 |
Triact Therapeutics, Inc. |
Cancer therapy
|
US9468681B2
(en)
|
2013-03-01 |
2016-10-18 |
California Institute Of Technology |
Targeted nanoparticles
|
ES2642201T3
(es)
|
2013-03-06 |
2017-11-15 |
Astrazeneca Ab |
Inhibidores de quinazolina de formas mutantes de activación del receptor del factor de crecimiento epidérmico
|
JP2016510751A
(ja)
|
2013-03-06 |
2016-04-11 |
ジェネンテック, インコーポレイテッド |
抗がん剤耐性を治療及び予防する方法
|
BR112015022545A2
(pt)
|
2013-03-13 |
2017-07-18 |
Constellation Pharmaceuticals Inc |
compostos de pirazolo e os usos disso
|
WO2014151871A2
(en)
|
2013-03-14 |
2014-09-25 |
Tolero Pharmaceuticals, Inc. |
Jak2 and alk2 inhibitors and methods for their use
|
EP2968565A2
(de)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
EP2968340A4
(de)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
Kombination von kinaseinhibitoren und verwendungen davon
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
WO2014147631A1
(en)
|
2013-03-22 |
2014-09-25 |
Natco Pharma Limited |
Formulation comprising gefitinib as oral suspension
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
CN103304491A
(zh)
*
|
2013-06-17 |
2013-09-18 |
连云港盛和生物科技有限公司 |
一种吉非替尼的制备方法
|
KR20150001936A
(ko)
*
|
2013-06-28 |
2015-01-07 |
제일약품주식회사 |
게피티닙의 신규한 결정형 및 이의 제조방법
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
EP3027623A4
(de)
*
|
2013-08-02 |
2017-03-01 |
Ignyta, Inc. |
Verfahren zur behandlung verschiedener karzinome mit einem axl/cmet-inhibitor allein oder in kombination mit anderen wirkstoffen
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
RU2016112568A
(ru)
|
2013-09-05 |
2017-10-06 |
Дженентек, Инк. |
Антипролиферативные соединения
|
EP3044593A4
(de)
|
2013-09-09 |
2017-05-17 |
Triact Therapeutics, Inc. |
Krebstherapie
|
CN105764924A
(zh)
|
2013-09-12 |
2016-07-13 |
哈洛齐梅公司 |
修饰的抗表皮生长因子受体抗体及其使用方法
|
MX2016003456A
(es)
|
2013-09-22 |
2017-05-25 |
Calitor Sciences Llc |
Compuestos aminopirimidina sustituidos y metodos de uso.
|
CN104513253A
(zh)
*
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
WO2015049325A1
(en)
|
2013-10-03 |
2015-04-09 |
F. Hoffmann-La Roche Ag |
Therapeutic inhibitors of cdk8 and uses thereof
|
EP3057615B1
(de)
|
2013-10-18 |
2021-02-24 |
F.Hoffmann-La Roche Ag |
Anti-rspo-antikörper und verfahren zur verwendung
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
TN2016000179A1
(en)
|
2013-12-06 |
2017-10-06 |
Novartis Ag |
Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
|
EP3083687A2
(de)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit ox40-bindungsagonisten und pd-1-achsenbindungsantagonisten
|
PT3083686T
(pt)
|
2013-12-17 |
2019-12-18 |
Hoffmann La Roche |
Métodos de tratamento de cancros com antagonistas da ligação ao eixo pd-1 e taxanos
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
WO2015128837A1
(en)
|
2014-02-26 |
2015-09-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
US10000469B2
(en)
|
2014-03-25 |
2018-06-19 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
WO2015148869A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
DK3126394T3
(da)
|
2014-03-31 |
2020-01-13 |
Hoffmann La Roche |
Anti-OX40-antistoffer og fremgangsmåder til anvendelse
|
CA2944401A1
(en)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2015170345A1
(en)
|
2014-05-09 |
2015-11-12 |
Council Of Scientific & Industrial Research |
Pharmaceutical cocrystals of gefitinib
|
RU2577518C2
(ru)
*
|
2014-06-02 |
2016-03-20 |
Олег Ростиславович Михайлов |
КРИСТАЛЛИЧЕСКАЯ БЕЗВОДНАЯ γ-МОДИФИКАЦИЯ 4-(3'-ХЛОР-4'-ФТОРАНИЛИНО)-7-МЕТОКСИ-6-(3-МОРФОЛИНОПРОПОКСИ)ХИНАЗОЛИНА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
|
US9617227B2
(en)
|
2014-06-10 |
2017-04-11 |
Scinopharm (Changshu) Pharmaceuticals, Ltd. |
Process of preparing a quinazoline derivative
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
EP3174869B1
(de)
|
2014-07-31 |
2020-08-19 |
Novartis AG |
Kombinationstherapie von einem met-hemmer und einem egfr-hemmer
|
HRP20221047T1
(hr)
|
2014-08-28 |
2022-11-11 |
Eisai R&D Management Co., Ltd. |
Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
|
TWI567063B
(zh)
*
|
2014-09-05 |
2017-01-21 |
國立交通大學 |
用於促進癌細胞凋亡的化合物、其醫藥組成物及其用途
|
WO2016036873A1
(en)
|
2014-09-05 |
2016-03-10 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
JP2017529358A
(ja)
|
2014-09-19 |
2017-10-05 |
ジェネンテック, インコーポレイテッド |
がんの処置のためのcbp/ep300阻害剤およびbet阻害剤の使用
|
EP3204379B1
(de)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidinamid-verbindungen als histondemethylase-inhibitoren
|
JP2017536347A
(ja)
|
2014-10-17 |
2017-12-07 |
ノバルティス アーゲー |
セリチニブとegfr阻害剤の組合せ
|
AU2015343339A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
|
CN106796235B
(zh)
|
2014-11-03 |
2021-01-29 |
豪夫迈·罗氏有限公司 |
用于检测t细胞免疫子集的测定法及其使用方法
|
JP2017534633A
(ja)
|
2014-11-06 |
2017-11-24 |
ジェネンテック, インコーポレイテッド |
Ox40結合アゴニスト及びtigit阻害剤を含む組み合わせ療法
|
EP3218376B1
(de)
|
2014-11-10 |
2019-12-25 |
Genentech, Inc. |
Bromodomaininhibitoren und deren verwendung
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
EP3221360A1
(de)
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit ox40-bindungsagonisten und pd-1-achsenbindungsantagonisten
|
JP6771464B2
(ja)
|
2014-11-27 |
2020-10-21 |
ジェネンテック, インコーポレイテッド |
Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物
|
AU2015355965B2
(en)
|
2014-12-04 |
2019-07-04 |
Delta-Fly Pharma, Inc. |
Novel PEG derivative
|
EP3233064A1
(de)
|
2014-12-19 |
2017-10-25 |
Synthon BV |
Pharmazeutische zusammensetzung mit gefifinib
|
JP2018508183A
(ja)
|
2014-12-23 |
2018-03-29 |
ジェネンテック, インコーポレイテッド |
化学療法耐性癌を治療及び診断する組成物及び方法
|
RU2739942C2
(ru)
|
2014-12-24 |
2020-12-30 |
Дженентек, Инк. |
Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
|
JP2018503373A
(ja)
|
2014-12-30 |
2018-02-08 |
ジェネンテック, インコーポレイテッド |
がんの予後診断及び治療のための方法及び組成物
|
NZ734220A
(en)
|
2015-01-06 |
2022-01-28 |
Arena Pharm Inc |
Methods of treating conditions related to the s1p1 receptor
|
WO2016112111A1
(en)
|
2015-01-08 |
2016-07-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Factors and cells that provide for induction of bone, bone marrow, and cartilage
|
EP3242875B1
(de)
|
2015-01-09 |
2022-02-23 |
Genentech, Inc. |
4,5-dihydroimidazol- derivate und ihre verwendung als histone demethylase (kdm2b) inhibitoren
|
CN107406414B
(zh)
|
2015-01-09 |
2022-04-19 |
基因泰克公司 |
作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物
|
WO2016112298A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
KR101635724B1
(ko)
*
|
2015-01-28 |
2016-07-05 |
일동제약주식회사 |
게피티닙의 개선된 제조방법
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
WO2016123391A1
(en)
|
2015-01-29 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
FI3263106T3
(fi)
|
2015-02-25 |
2024-01-03 |
Eisai R&D Man Co Ltd |
Menetelmä kinoliinijohdannaisen kitkeryyden tukahduttamiseksi
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
WO2016150340A1
(zh)
*
|
2015-03-20 |
2016-09-29 |
正大天晴药业集团股份有限公司 |
喹唑啉衍生物的盐及其制备方法
|
CN107709364A
(zh)
|
2015-04-07 |
2018-02-16 |
豪夫迈·罗氏有限公司 |
具有激动剂活性的抗原结合复合体及使用方法
|
MX2017014381A
(es)
|
2015-05-12 |
2018-03-02 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para cancer.
|
PL3303632T5
(pl)
|
2015-05-29 |
2023-07-03 |
F. Hoffmann-La Roche Ag |
Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
|
WO2016200836A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
EP3303397A1
(de)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Verfahren zur krebsbehandlung mit anti-ox40-antikörpern und pd-1-achsen-bindungsantagonisten
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
CN108349891B
(zh)
|
2015-06-22 |
2022-04-05 |
艾尼纳制药公司 |
用于s1p1受体相关病症的化合物的结晶l-精氨酸盐
|
EP3317323B1
(de)
|
2015-07-01 |
2021-05-26 |
California Institute of Technology |
Kationische schleimsäurepolymerbasierte abgabesysteme
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
WO2017033019A1
(en)
|
2015-08-26 |
2017-03-02 |
Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii (Cnio) |
Condensed tricyclic compounds as protein kinase inhibitors
|
AR105910A1
(es)
|
2015-09-04 |
2017-11-22 |
Obi Pharma Inc |
Matrices de glicano y método de uso
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
GB201516905D0
(en)
|
2015-09-24 |
2015-11-11 |
Stratified Medical Ltd |
Treatment of Neurodegenerative diseases
|
CN105250228B
(zh)
*
|
2015-10-12 |
2017-10-24 |
山东罗欣药业集团股份有限公司 |
一种吉非替尼的片剂及其原料的制备方法
|
MX2018005298A
(es)
|
2015-11-02 |
2018-06-22 |
Novartis Ag |
Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
|
BR112018011228A2
(pt)
|
2015-12-01 |
2019-01-15 |
Glaxosmithkline Ip Dev Ltd |
tratamentos de combinação e seus usos e métodos
|
DK3389662T3
(da)
|
2015-12-16 |
2022-02-28 |
Genentech Inc |
Fremgangsmåde til fremstilling af tricykliske PI3K-inhibitorforbindelser og fremgangsmåder til anvendelse af disse til behandling af cancer
|
ES2851499T3
(es)
|
2015-12-30 |
2021-09-07 |
Synthon Bv |
Proceso para fabricar una forma cristalina de gefitinib
|
CN105503748A
(zh)
*
|
2015-12-31 |
2016-04-20 |
哈药集团技术中心 |
一种吉非替尼的制备方法
|
IL259588B2
(en)
|
2016-01-08 |
2023-09-01 |
Hoffmann La Roche |
Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3
|
WO2017151502A1
(en)
|
2016-02-29 |
2017-09-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
TWI780045B
(zh)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
抗體、醫藥組合物及方法
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
ES2850428T3
(es)
|
2016-04-15 |
2021-08-30 |
Hoffmann La Roche |
Procedimientos de monitorización y tratamiento del cáncer
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2017181079A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
US11261187B2
(en)
|
2016-04-22 |
2022-03-01 |
Duke University |
Compounds and methods for targeting HSP90
|
KR20230110820A
(ko)
|
2016-04-22 |
2023-07-25 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
|
EP3454863A1
(de)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Kombinationstherapien zur behandlung von krebs
|
KR101796684B1
(ko)
*
|
2016-05-19 |
2017-11-10 |
건국대학교 산학협력단 |
케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
|
JP7014736B2
(ja)
|
2016-05-24 |
2022-02-01 |
ジェネンテック, インコーポレイテッド |
がんの処置のためのピラゾロピリジン誘導体
|
CN109476641B
(zh)
|
2016-05-24 |
2022-07-05 |
基因泰克公司 |
Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
|
CN106045980B
(zh)
*
|
2016-06-03 |
2017-11-03 |
江苏开放大学 |
一种喹唑啉衍生物及其制备方法
|
EP3469099A1
(de)
|
2016-06-08 |
2019-04-17 |
F. Hoffmann-La Roche AG |
Diagnose- und therapieverfahren für krebs
|
ES2963807T3
(es)
|
2016-06-08 |
2024-04-02 |
Xencor Inc |
Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B
|
CA3032049C
(en)
|
2016-07-27 |
2023-11-07 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
EP3491026A4
(de)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
|
WO2018025221A1
(en)
|
2016-08-04 |
2018-02-08 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-icos and anti-pd-1 antibody combination therapy
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック, インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
EP3503914A1
(de)
|
2016-08-23 |
2019-07-03 |
Oncopep, Inc. |
Peptidimpfstoffe und durvalumab zur behandlung von brustkrebs
|
CN106432202B
(zh)
*
|
2016-09-22 |
2019-04-02 |
郑州大学第一附属医院 |
喹唑啉类衍生物及其应用
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
EP4089116A1
(de)
|
2016-09-27 |
2022-11-16 |
Cero Therapeutics, Inc. |
Chimäre engulfment-rezeptormoleküle
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
EP3541414A4
(de)
|
2016-11-21 |
2020-11-11 |
OBI Pharma, Inc. |
Konjugierte biologische moleküle, pharmazeutische zusammensetzungen und verfahren
|
ES2894255T3
(es)
|
2016-12-22 |
2022-02-14 |
Amgen Inc |
Derivados de benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibidores de KRAS G12C para tratar el cáncer de pulmón, pancreático o colorrectal
|
MX2019010295A
(es)
|
2017-03-01 |
2019-11-21 |
Genentech Inc |
Métodos de diagnóstico y terapéuticos para el cáncer.
|
US9980967B1
(en)
|
2017-03-16 |
2018-05-29 |
National Chiao Tung University |
Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
|
MX2019012187A
(es)
|
2017-04-13 |
2019-11-25 |
Hoffmann La Roche |
Un inmunoconjugado de interleuquina-2, un agonista de cd40 y opcionalmente un antagonista de union al eje pd-1 para uso en metodos para tratar cancer.
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
KR20200093518A
(ko)
|
2017-07-21 |
2020-08-05 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
KR20200037366A
(ko)
|
2017-08-11 |
2020-04-08 |
제넨테크, 인크. |
항-cd8 항체 및 이의 용도
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
EP3679159A1
(de)
|
2017-09-08 |
2020-07-15 |
H. Hoffnabb-La Roche Ag |
Diagnose- und therapieverfahren für krebs
|
MX2020007266A
(es)
|
2017-09-26 |
2020-09-07 |
Cero Therapeutics Inc |
Moleculas del receptor quimerico de engullido y metodos de uso.
|
CA3079422A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
CN109721552B
(zh)
*
|
2017-10-30 |
2022-09-20 |
上海北卡医药技术有限公司 |
一种吉非替尼的制备方法
|
JP2021502066A
(ja)
|
2017-11-06 |
2021-01-28 |
ジェネンテック, インコーポレイテッド |
がんの診断及び療法
|
EP3710006A4
(de)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
Substituierte heteroarylverbindungen und verfahren zur verwendung
|
WO2019126136A2
(en)
|
2017-12-18 |
2019-06-27 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
JP7450541B2
(ja)
|
2018-01-20 |
2024-03-15 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
置換アミノピリミジン化合物及び使用方法
|
CN117402114A
(zh)
|
2018-01-26 |
2024-01-16 |
埃克塞里艾克西斯公司 |
用于治疗激酶依赖性病症的化合物
|
PE20210044A1
(es)
|
2018-01-26 |
2021-01-08 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de cinasas
|
WO2019148043A1
(en)
|
2018-01-26 |
2019-08-01 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
AU2019225249A1
(en)
|
2018-02-26 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
|
JP7444781B2
(ja)
|
2018-03-28 |
2024-03-06 |
セロ・セラピューティクス・インコーポレイテッド |
細胞免疫療法組成物およびその使用
|
WO2019191334A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
CA3093969A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
WO2019195753A1
(en)
|
2018-04-05 |
2019-10-10 |
Tolero Pharmaceuticals, Inc. |
Axl kinase inhibitors and use of the same
|
EP3788053A1
(de)
|
2018-05-04 |
2021-03-10 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
WO2019213516A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CN108395410A
(zh)
*
|
2018-05-09 |
2018-08-14 |
日照市普达医药科技有限公司 |
一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
EP3797173A2
(de)
|
2018-05-21 |
2021-03-31 |
Nanostring Technologies, Inc. |
Molekulare gensignaturen und verfahren zu deren verwendung
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
AU2019284472A1
(en)
|
2018-06-11 |
2020-11-26 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
EP3807276A2
(de)
|
2018-06-12 |
2021-04-21 |
Amgen Inc. |
Einen piperazinring umfassende kras g12c-inhibitoren und ihre verwendung zur krebsbehandlung
|
SG11202012446UA
(en)
|
2018-06-23 |
2021-01-28 |
Genentech Inc |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
TW202011991A
(zh)
|
2018-07-18 |
2020-04-01 |
美商建南德克公司 |
用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
JP2021530554A
(ja)
|
2018-07-26 |
2021-11-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤
|
EP3847154A1
(de)
|
2018-09-03 |
2021-07-14 |
F. Hoffmann-La Roche AG |
Carboxamid- und sulfonamidderivate zur verwendung als tead-modulatoren
|
CN112955747A
(zh)
|
2018-09-19 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
膀胱癌的治疗和诊断方法
|
ES2955032T3
(es)
|
2018-09-21 |
2023-11-28 |
Hoffmann La Roche |
Métodos de diagnóstico para el cáncer de mama triple negativo
|
AU2019352741A1
(en)
|
2018-10-04 |
2021-05-06 |
Assistance Publique-Hôpitaux De Paris (Aphp) |
EGFR inhibitors for treating keratodermas
|
MX2021004348A
(es)
|
2018-10-18 |
2021-05-28 |
Genentech Inc |
Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
EP3883565A1
(de)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
JP2022515197A
(ja)
|
2018-12-19 |
2022-02-17 |
アレイ バイオファーマ インコーポレイテッド |
がんを治療するためのfgfr阻害剤としての7-((3,5-ジメトキシフェニル)アミノ)キノキサリン誘導体
|
EP3898626A1
(de)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituierte pyrazolo[1,5-a]pyridin-verbindungen als inhibitoren von fgfr-tyrosinkinasen
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
JP2022513971A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
AU2019404576A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
JP7407196B2
(ja)
|
2018-12-20 |
2023-12-28 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
CA3124330A1
(en)
|
2018-12-21 |
2020-06-25 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
US20220098303A1
(en)
|
2019-02-01 |
2022-03-31 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
|
JP2022519649A
(ja)
|
2019-02-08 |
2022-03-24 |
ジェネンテック, インコーポレイテッド |
がんの診断および治療方法
|
AU2020227319A1
(en)
|
2019-02-27 |
2021-09-09 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing T-cell function and predicting response to therapy
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
SG11202109422WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heterocyclyl compounds and uses thereof
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
AU2020280024A1
(en)
|
2019-05-21 |
2021-12-09 |
Amgen Inc. |
Solid state forms
|
CN114222760A
(zh)
|
2019-06-26 |
2022-03-22 |
葛兰素史密斯克莱知识产权发展有限公司 |
Il1rap结合蛋白
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
AU2020326627A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
EP4007756A1
(de)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a-inhibitoren
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
WO2021046159A1
(en)
|
2019-09-04 |
2021-03-11 |
Genentech, Inc. |
Cd8 binding agents and uses thereof
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
WO2021046293A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
|
CA3155924A1
(en)
|
2019-09-26 |
2021-04-01 |
Exelixis, Inc. |
PYRIDONE COMPOUNDS AND METHODS OF USE IN MODULATING A PROTEIN KINASE
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
CA3155857A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
|
CN114728936A
(zh)
|
2019-10-29 |
2022-07-08 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的双功能化合物
|
BR112022008534A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
US20220389103A1
(en)
|
2019-11-06 |
2022-12-08 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
CN116425742A
(zh)
|
2019-11-08 |
2023-07-14 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
US20210161897A1
(en)
|
2019-11-12 |
2021-06-03 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
TW202130618A
(zh)
|
2019-11-13 |
2021-08-16 |
美商建南德克公司 |
治療性化合物及使用方法
|
AR120457A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
EP4058465A1
(de)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4-antagonistenpeptide
|
EP4058432A1
(de)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Verbesserte synthese einer kras-g12c-hemmenden verbindung
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
CR20230210A
(es)
|
2019-12-13 |
2023-06-14 |
Genentech Inc |
ANTICUERPOS ANTI-LY6G6D Y MÉTODOS DE USO (Divisional 2022-0330)
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
CN114929279A
(zh)
|
2020-01-07 |
2022-08-19 |
锐新医药公司 |
Shp2抑制剂给药和治疗癌症的方法
|
WO2021148396A1
(en)
|
2020-01-20 |
2021-07-29 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
IL294800A
(en)
|
2020-01-27 |
2022-09-01 |
Genentech Inc |
Methods of treating cancer with an antibody to an anti-ti antagonist
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
US20230067202A1
(en)
|
2020-01-28 |
2023-03-02 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
JP2023517393A
(ja)
*
|
2020-03-17 |
2023-04-25 |
メッドシャイン ディスカバリー インコーポレイテッド |
タンパク質分解調整剤およびその使用方法
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
CN113801068A
(zh)
*
|
2020-06-15 |
2021-12-17 |
鲁南制药集团股份有限公司 |
一种吉非替尼的有机酸盐
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
CA3181672A1
(en)
|
2020-06-18 |
2021-12-23 |
Shi Li |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
MX2022016355A
(es)
|
2020-06-18 |
2023-04-03 |
Revolution Medicines Inc |
Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
|
EP4172621A1
(de)
|
2020-06-30 |
2023-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur vorhersage des risikos des wiederauftretens und/oder tods von patienten mit solidem krebs nach präoperativen adjuvanten therapien
|
CN115843335A
(zh)
|
2020-06-30 |
2023-03-24 |
国家医疗保健研究所 |
用于预测患有实体癌的患者在术前辅助治疗和根治性手术后复发和/或死亡风险的方法
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック, インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
EP4192509A1
(de)
|
2020-08-05 |
2023-06-14 |
Ellipses Pharma Ltd |
Behandlung von krebs mit einem cyclodextrinhaltigen polymer-topoisomerase-inhibitor-konjugat und einem parp-inhibitor
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
IL300930A
(en)
|
2020-08-27 |
2023-04-01 |
Enosi Therapeutics Corp |
Methods and compositions for the treatment of autoimmune diseases and cancer
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
WO2022060836A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Indole derivatives as ras inhibitors in the treatment of cancer
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2022076462A1
(en)
|
2020-10-05 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
CA3203111A1
(en)
|
2020-12-22 |
2022-06-30 |
Kailiang Wang |
Sos1 inhibitors and uses thereof
|
CN112321814B
(zh)
*
|
2020-12-30 |
2021-03-23 |
广州初曲科技有限公司 |
一种吉非替尼艾地苯醌轭合物的制备及用途
|
KR20230146052A
(ko)
|
2021-02-12 |
2023-10-18 |
에프. 호프만-라 로슈 아게 |
암 치료용 비시클릭 테트라히드로아제핀 유도체
|
CA3211063A1
(en)
|
2021-02-19 |
2022-08-25 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
BR112023017213A2
(pt)
|
2021-02-26 |
2023-11-21 |
Kelonia Therapeutics Inc |
Vetores lentivirais direcionados a linfócitos
|
KR20240004960A
(ko)
|
2021-05-05 |
2024-01-11 |
레볼루션 메디슨즈, 인크. |
Ras 억제제
|
EP4334324A1
(de)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Kovalente ras-inhibitoren und verwendungen davon
|
PE20240089A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cancer
|
WO2022251296A1
(en)
|
2021-05-25 |
2022-12-01 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
CN113527266A
(zh)
*
|
2021-06-23 |
2021-10-22 |
上海健康医学院 |
一种靶向fap的双氧水响应的前药及其制备方法与应用
|
CN113336742B
(zh)
|
2021-06-29 |
2022-05-10 |
山东金吉利新材料有限公司 |
一种马来酸吡咯替尼中间体的合成方法
|
CA3226019A1
(en)
|
2021-07-20 |
2023-01-26 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their preparation, and uses
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2023018699A1
(en)
|
2021-08-10 |
2023-02-16 |
Erasca, Inc. |
Selective kras inhibitors
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
CN113845485B
(zh)
*
|
2021-10-22 |
2023-03-14 |
湖南中医药大学 |
氨基酸衍生物及其制备方法和应用
|
WO2023097194A2
(en)
|
2021-11-24 |
2023-06-01 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023187037A1
(en)
|
2022-03-31 |
2023-10-05 |
Astrazeneca Ab |
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024002938A1
(en)
|
2022-06-27 |
2024-01-04 |
Astrazeneca Ab |
Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|